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1. Introduction  
In 1958, Menghini published the first description of liver biopsy (LB) as it pertained to the 
study of fibrosis. Since then, LB has become the “gold  standard” in the evaluation of liver 
fibrosis. However, the use of LB has several limitations, including physical and mental 
discomfort of patients, which may lead to a high percentage of refusals, non-negligible 
morbidity and occasional mortality. Fibrosis is evaluated by histological semiquantitative 
scores, among which the METAVIR fibrosis scoring system is the most used; it is able to 
detect different degrees of fibrosis, from absence of fibrosis (F0) to cirrhosis (F4), and shows 
a better intra- and inter-observer reproducibility than other scales (i.e., Brunt, Knodell, Ishak 
and Scheuer). However these scores do not provide a dynamic picture of the disease, but 
only information about diagnosis and prognosis, such as the necroinflammatory activity and 
the presence of steatosis (Abenavoli et al, 2007). 
Non-alcoholic fatty liver disease (NAFLD) is a relevant issue in public health because of its 
epidemiologic burden (Argo & Caldwell, 2009). NAFLD is also not a new condition, but was 
not appreciated in early reports. It represents the most common chronic liver disease in the 
general population and is expected to increase in the future as a result of an ageing population, 
the improving control of other major causes of chronic liver disease and the epidemics of 
obesity and diabetes (Abenavoli et al, 2011). Steatosis consists of an accumulation of fat in the 
liver cells, and is not a disease in and of itself. It is an aggravating factor in certain pathological 
situations of varying degrees of gravity, and becomes dangerous when associated with 
inflammation or fibrosis. It is reversible, however, through diet and exercise. In fact NAFLD, 
may present as a spectrum ranging from asymptomatic steatosis with elevated or normal 
aminotransferases to steatohepatitis [non-alcoholic steatohepatitis (NASH)], all the way to 
cirrhosis with complications of liver function to hepatocellular carcinoma. NAFLD occurs in 
60-95% patients with obesity, in 28-55% patients with type 2 diabetes mellitus (T2DM) and in 
27-92% patients with dyslipidemia. Insulin resistance with compensatory hyperinsulinemia is 
the common denominator of obesity, T2DM and dyslipidemia and it can play a pathogenetic 
role in NAFLD. Accordingly, it has been reported that insulin resistance is the single 
laboratory finding most closely associated with NAFLD in a large series of patients, 
irrespective of body mass index (BMI), fat distribution, or glucose tolerance. Indeed, NAFLD 
has been recently proposed as an additional feature of the metabolic syndrome. 
Currently liver steatosis, can be detected only by ultrasound (US) and quantified only by 






broad range of NAFLD. However LB is not recommended in NAFLD patients, because of its 
cost, the potential risk of bleeding, and the absence of consensus regarding the histopatological 
criteria that firmly define NASH and differentiate between NAFLD entities. Due to the 
remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing 
new therapies for fatty liver, non-invasive, simple, reproducible, and reliable non-invasive 
techniques are needed. In this way US is widely used in the diagnosis of patients with 
suspected liver disease because it is highly accurate, relatively inexpensive and non-invasive. 
Based on these characteristics, US has been the first-line imaging technique suitable both in the 
clinical setting and for epidemiological studies. In particular US is the least expensive modality 
for detecting changes associated with NAFLD. However, echography-based US techniques 
begin to become sensitive at moderately high levels of steatosis (33% or more) and suffer from 
low intra- and inter-operator repeatability (Schwenzer et al, 2009). 
Vibration-controlled transient elastography ([VCTE], Fibroscan®, Echosens, Paris, France) is 
a non-invasive technique which measures liver stiffness, and allows the assessment of the 
extent of hepatic fibrosis. VCTE has been proposed for the measurement of liver stiffness, 
considered to be one of the direct consequences of the fibrotic evolution of chronic liver 
disease (Sandrin et al, 2003).  
A few meta-analyses have suggested liver stiffness measurement (LSM) through VCTE to be a 
reliable tool to detect advanced liver fibrosis and early liver cirrhosis (Friedrich-Rust et al, 
2008). In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear 
wave, but it does not change its underlying speed which is the parameter used for stiffness 
measurement. Literature showed a clearly positive correlation between liver stiffness and the 
severity of liver fibrosis in patients with NAFLD. Rapid, non-invasive estimation of the stage 
of fibrosis in NAFLD patients, especially NASH patients, is of major clinical interest because 
such patients have been shown to be at a high risk of developing complications. Recently, a 
new measurement technique, the controlled attenuation parameter (CAP®, EchoSens, Paris, 
France), which provides good accuracy with even low levels of steatosis in the liver has been 
introduced. Because of its sensitivity at early phases of steatosis. CAP could provide a means 
to monitor the progression or regression of steatosis.  
The combination of the measurement of liver attenuation parameter (CAP) and liver 
stiffness (VCTE) could provide a means to follow NAFLD patients throughout the course of 
the disease and observe independently the effects of steatosis and liver injury effects that are 
signs of the worsening of the disease. 
2. Transient elastography for staging liver disease 
The development of non-invasive tools to evaluate liver disease stages, has emerged as a 
major clinical and research priority. The quest for accurate techniques to stage NAFLD 
stems from a variety of recent data. First, the prevalence of NAFLD has grown to epidemic 
proportions. It is currently one of the most common chronic liver diseases worldwide. It is 
strongly associated with metabolic syndrome and obesity, and may progress to cirrhosis 
and hepatocellular carcinoma. The prognosis depends heavily on histological severity. 
Although patients with simple steatosis have excellent prognosis, those with NASH tend to 
progress and have hepatic complications. In Western countries, one in three men and nearly 
every other woman is affected by NAFLD. Second, it is well reported that NAFLD exists as a 
spectrum consisting of two major phenotypes that have drastically different natural 
histories. The majority of patients present simple steatosis, which has a benign clinical 
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course. However 10-20% of these individuals present NASH that can evolve into cirrhosis. 
Third, according to literature, several problems for the management of NAFLD patients in 
clinical practice still exist: how to diagnose NAFLD and its type, how to select patient 
candidates for treatment and how to treat the patients selected. Discovery and validation of 
new diagnostic tools for NAFLD have several potential benefits, including reduced risk, 
reduced cost, as well as insights into disease mechanisms and pathogenesis. More accurate 
detection and diagnosis of NAFLD will help focus service provision for what is already a 
very common condition. 
The limitations of LB (invasive procedure, sampling errors, interobserver variability and non-
dynamic evaluation) have stimulated the search for non-invasive approaches for the 
assessment of steatosis and liver fibrosis in patients with NAFLD. A variety of new methods, 
including serum markers, imaging techniques such as US, computed tomography, magnetic 
resonance imaging and VCTE, and more recently, CAP, have been proposed. In particular 
VCTE has shown excellent results for the diagnosis of severe fibrosis and cirrhosis and 
moderate results for the diagnosis of significant fibrosis in patients with NAFLD/NASH. 
The stiffness of a body is defined as the ability of the body to deform itself under the action 
of a mechanical force (Abenavoli et al, 2007). The stiffness of a soft tissue can be estimated 
on the basis of the speed of propagation of a transverse shear elastic wave. The higher is the 
speed of propagation of that wave, the higher is the stiffness of the tissue. VCTE measures 
such speed of propagation in relatively homogenous organs like the liver, by using US 
pulses to localise the shear elastic wave at different times. The measuring device is equipped 
with a probe consisting of an ultrasonic transducer mounted on the axis of a vibrator. A 
low-frequency at 50 Hz and mild amplitude vibration, referred to as “shots”, is transmitted 
from the vibrator to the tissue by the transducer itself. This vibration induces an elastic shear 
wave which propagates through the tissue. In the meantime, ultrasonic acquisitions are 
performed by an echographic transducer, using a frequency at 3.5MHz, to determine the 
propagation of the shear wave. The propagation speed is transformed into stiffness by a 
formula derived by the physics of the propagation of a transverse shear elastic wave of a 
given frequency (50 Hz) through the soft tissue and expressed in kiloPascals (kPa). The 
probe is applied perpendicularly to the skin (with a little gel film) through one of the right 
side intercostal spaces along the mid-axillary line. The measurement of the speed is taken 
along a cylinder of tissue ranging from 25 to 65 millimetres of depth under the skin. This 
corresponds to a volume of liver tissue approximately 100 times greater than an LB 
specimen and represents about 1% of the total organ volume. The examination is non-
invasive and can be performed on ambulatory patients, in an outpatient setting or at the 
bedside of a hospitalized patient. VCTE can be performed indifferently by hepatologists or 
medical staff (physician, resident, medicine student, nurse) after a single training session 
provided by a specifically certified trainer. Results of the measurements range from 1.3 and 
75.4 kPa. The manufacturer currently recommends that fibrosis score should be established 
from the median value of at least 10 successful acquisitions, with the rate of valid measures 
always higher than 50%. The intra- and inter-observer coefficients of variation are 3.2 and 
3.3%, respectively, indicating very good reproducibility and operator independence.  
3. Elastography assessment of fatty liver 
A prospective study (Kim et al., 2007) aimed to assess the ability of VCTE to identify 






potential liver donors, and to compare these findings with results in liver disease patients. 
Forty-seven patients with abnormal liver function and/or hepatitis symptoms and 80 living 
related potential liver donors were consecutively enrolled, and LB and a LSM was 
performed in each subject. Histologic parameters were evaluated according to METAVIR 
score by a single pathologist. In liver disease patients, stiffness was significantly correlated 
with fibrosis stage (P< 0.001), and the optimal stiffness cut-off values for F≥2, F≥3, and F=4 
were 7.35, 8.85, and 15.1 kPa respectively. In potential liver donors, stiffness was not 
correlated with fibrosis ( P = 0.851). In the latter group, the area under the receiver-operating 
characteristics curve (AUROC) was 0.70 (95%, confidence interval [CI],  0.58-0.81), and the 
optimal stiffness cut-off value was 4.00 kPa for F ≥ 2, which was lower than that in liver 
disease patients. Steatosis was not correlated with stiffness (P = 0.463) in potential liver 
donors. The Authors concluded that VCTE presets limited value for detecting steatosis in 
asymptomatic healthy individuals. 
Nobili et al. (2008) have been assessed the value of VCTE in a cohort of pediatric patients 
with NASH. TE was performed in 50 consecutive biopsy-proven NASH patients age 
13.6±2.44 years). The AUROC for the prediction of different degrees of liver fibrosis on the 
basis of Brunt score, were 0.977, 0.992, and 1, for respectively “any”, significant and 
advanced fibrosis. Calculation of multilevel likelihood ratios shows that VCTE values <5, 
<7, and <9 kPa, suggest the presence of “any” fibrosis, significant fibrosis, and advanced 
fibrosis, respectively. VCTE values between 5 and 7 kPa predict a fibrosis stage of 1, but 
with some degree of uncertainty. VCTE values between 7 and 9 kPa predict fibrosis stages 1 
or 2, but cannot discriminate between these two stages. VCTE values of at least 9 kPa are 
associated with the presence of advanced fibrosis. In summary this study reported the 
reliability of VCTE to predict the presence of “any” fibrosis, significant fibrosis, and 
advanced fibrosis in these special populations. 
Yoneda et al. (2008) have been investigated the usefulness of LSM in the evaluation of liver 
fibrosis in NAFLD patients. VCTE was performed for liver stiffness measurement in 97 
NAFLD patients. The Authors have also investigated the relationship between LSM and the 
serum levels of hyaluronic acid and type IV collagen 7s domain. Liver stiffness was well 
correlated with the different stage of METAVIR score (P<0.0001). The AUROC were 0.927 
for ≥F1, 0.865 for ≥F2, 0.904 for ≥F3, 0.991 for ≥F4. Only fibrosis stage was strictly correlated 
with liver stiffness measurement by multiple regression analysis. Liver stiffness was also 
strongly correlated with the serum levels of type IV collagen 7s domain (r=0.525, P<0.0001) 
and hyaluronic acid (r=0.457, P<0.0001). These data show a significant correlation between 
liver stiffness measurement and fibrosis stage in NAFLD patients, as confirmed by the 
results of LB.  
Lupsor et al. (2010) assess VCTE performance in NASH patients, as well as the factors 
determining the discordance between the VCTE-predicted and the fibrosis stage evaluated 
by the Brunt system. LB and VCTE were performed on 72 consecutive NASH patients. LSM 
ranged from 2.80 to 16.90 kPa. In the univariate analysis, LSM was correlated with fibrosis 
(P<0.0001), steatosis (P<0.0001), ballooning (P=0.001) and lobular inflammation (P=0.002). In 
multivariate analysis, only fibrosis significantly correlated with LS (P<0.0001). The median 
LSM values according to the fibrosis stages were: 4.90 kPa (range: 2.80-7.30) for F0; 6.15 kPa 
(4.80-12.50) for F1; 6.90 kPa (3.30-16.90) for F2 and 14.00 kPa (10.70-14.10) for F3, with 
significant difference between stages, except for F1-F2 (P=0.249). Cut-off values were 
calculated for predicting each fibrosis stage: 5.3kPa (AUROC=0.879) for F1; 6.8kPa 
(AUROC=0.789) for F2; and 10.4kPa (AUROC=0.978) for F3. Patients with false positive 
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results had a significantly higher ALT level than those with concordant results (P=0.039). 
These data show that steatosis degree, ballooning and inflammation do not influence LSM. 
In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear wave, 
possibly leading again to an underestimation of liver damage. Wong et al. (2010) aimed to 
evaluate the accuracy of VCTE in the diagnosis of fibrosis and cirrhosis in patients with 
NAFLD and to study factors associated with discordance between LSM and histology. Two 
hundred forty-six consecutive patients from two ethnic groups had successful LSM and 
satisfactory liver biopsy specimens. The AUROC of VCTE for F3 or higher and F4 disease was 
0.93 and 0.95, respectively, and was significantly higher than that of other prediction scores 
(e.g. aspartate aminotransferase–to–alanine aminotransferase ratio, aspartate 
aminotransferase–to–platelet ratio index, FIB-4, BARD, and NAFLD fibrosis scores). AUROC 
ranged from 0.62 to 0.81, P < 0.05 for all comparisons. At a cut-off value of 7.9 kPa, the 
sensitivity, specificity, and positive and negative predictive values for F3 or greater disease 
were 91%, 75%, 52%, and 97%, respectively. LSM was not affected by hepatic steatosis, 
necroinflammation, or body mass index. Discordance of at least two stages between VCTE and 
histology was observed in 33 (13.4%) patients. By multivariate analysis, a LB length less than 
20 mm and F0-2 disease, rather than VCTE, were associated with discordance. Unsatisfactory 
LB specimens rather than VCTE account for most cases of discordance. However, when the 
diagnostic characteristics were compared using an “intention to diagnose” approach with the 
inclusion of subjects who had unsuccessful TE acquisition, the sensitivity and specificity values 
were not dissimilar from the clinical/biochemical models, although 95% CIs were not 
provided for statistical comparison.  
Subsequently a prospective study by Gaia et al. (2011) assess the accuracy and the efficacy of 
VCTE for the detection of fibrosis in patients with liver disease of different etiology (chronic 
hepatitis B - CHB, C- CHC and NAFLD) and evaluate the effect of steatosis on LSM. VCTE 
was performed in 219 consecutive patients with chronic liver disease (35% CHC, 32% CHB, 
and 33% NAFLD) within 6 months of the liver biopsy. LSM was related to the fibrosis stage 
in each group (CHC: P=0.596, P<0.001; CHB: P =0.418, P<0.001; NAFLD: P=0.573, P<0.001), 
but the correlation was less strong in CHB and NAFLD than in CHC patients. Median LSM 
values were 7 kPa (3.2–26) in HCV patients (n=77), 7.6 kPa (3.7–30.7) in HBV patients (n=70), 
6.6 kPa (3.0–44.3) in NAFLD patients (n=72) compared to 4.35 kPa (range 2.6–7) in controls 
(n=40), (P<0.001). The median values of LSM according to fibrosis stage evaluated by 
METAVIR were in the 72 NAFLD patients: F0: 5.3 kPa (3.0–9.7), F1: 6.15 kPa (3.2–12.1), 
F2:7.75 kPa (4.3–13.9), F3:6.5 kPa (4.3–10.3), F4:11.9 kPa (7.9–44.3), (P=0.001). VCTE 
underestimated the stage of fibrosis in 75% of patients with F3 and steatosis >33%. At 
multiple logistic regression analysis, in CHC and CHB patients, LSM was the only 
predictive variable of severe fibrosis/cirrhosis (odds ratio [OR]=1.42, P=0.003 and OR=1.354, 
P=0.003, respectively), while in NAFLD subjects BMI and AST (OR=1.433, P=0.002 and 
OR=1.053, P=0.020, respectively) but not LSM were independently related with advanced 
fibrosis and cirrhosis. This study confirms that VCTE can be considered a valid support to 
detect fibrosis in chronic liver disease related to HCV but it should be interpreted cautiously 
in CHB and NAFLD patients. 
4. Elastography assessment of NAFLD in obese patients 
LSM can be influenced by metabolic syndrome even in the absence of biological features in 






LSM or LSM failure, as the results may provide guidance to referral physicians regarding 
the optimal candidates for LSM. The knowledge would also assist clinicians to counsel 
patients before arranging LSM. However, studies have shown that BMI>28 is an 
independent risk factor for a LSM failure (Foucher et al, 2006). In a prospective pilot study 
on VCTE in NAFLD, de Lédinghen et al. (2010) aimed to assess the feasibility of LSM when 
using a new XL-probe on patients with a BMI≥30 kg/m2 is used. In this study 99 patients 
(mean  BMI 40.5 kg/m2) were included. LSM was successful in 45% of the cases with the M 
probe, versus 76% of the cases with the XL-probe (P<0.001). Fifty-nine percent of those who 
could not be measured (<10 valid measurements) using the M-probe could successfully be 
measured using the XL-probe. In the 44 patients successfully measured with both probes, 
LSM was correlated with the platelet count, prothrombin time, gamma-glutamyltransferase, 
aspartate aminotransferase, fasting glucose, AST platelet ratio index, Forns score and FIB-4. 
The XL-probe allows providing a higher rate of LSM than the M-probe in patients with an 
increased BMI and shows promising results for the evaluation of liver fibrosis. 
 
Lead author Yoneda (N 97)* Nobili (N 50)° Lupsor (N 72)° Wong (N 246)° 
F≥ 2     
AUROC 0.86 0.99 0.78 0.84 
Optimal cut-off (kPa) 6.6 7.4 6.8 7.0 
Sensitivity (%) 88 100 100 79 
Specificity (%) 74 92 97 76 
PPV (%) 79 80 71 70 
NPV (%) 85 100 100 84 
F≥ 3     
AUROC 0.90 1.0 0.978 0.93 
Optimal cut-off (kPa) 9.8 10.2 10.4 8.7 
Sensitivity (%) 85 100 100 84 
Specificity (%) 81 100 97 83 
PPV (%) 64 100 71 59 
NPV (%) 93 100 100 95 
F≥ 3     
AUROC 0.99 - - 0.95 
Optimal cut-off (kPa) 17.5   10.3 
Sensitivity (%) 100 - - 92 
Specificity (%) 97 - - 88 
PPV (%) 75 - - 46 
NPV (%) 100 - - 99 
Table 1. Analysis of VCTE cut-off for the diagnosis of NAFLD in adult patients. (AUROC: 
area under receiver operative curve; PPV: positive predictive value; NPV: negative 
predictive value. Histological evaluation by *METAVIR and °Brunt score). 
In this way Wong et al. (2011) have recently investigated the rates of unreliable LSM and 
LSM failure in patients suffering from chronic liver diseases. They also aimed to evaluate 
the factors including BMI and central obesity associated with unreliable LSM and LSM 
failure. Among 3205 Chinese patients with LSM, 370 (12%) with liver steatosis, 371 
(11.6%) and 88 (2.7%) had unreliable LSM and LSM failure, respectively. The rates started 
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to increase when BMI≥28.0 kg/m2. Comparing patients with BMI≥28.0-29.9 kg/m2 vs 
those with BMI≥30.0 kg/m2, the rates of unreliable LSM (16.4% vs 18.9%; P=0.62) and LSM 
failure (11.8% vs 17.8%; P=0.16) were similar. BMI≥28.0 kg/m2 was the most important 
factor associated with unreliable LSM (OR=2.9, 95% CI=2.1–3.9, P<0.0001) and LSM 
failure (OR=10.1, 95% CI=6.4–14.2, P<0.0001). Central obesity, defined as waist 
circumference >80 cm in women and >90 cm in men, was another independent risk factor 
of unreliable LSM (OR=1.3, 95% CI=1.0–1.6, P=0.04) and LSM failure (OR=5.8, 95% 
CI=2.9–11.5, P<0.0001). 
5. Controlled attenuation parameter and liver steatosis 
Fat affects US propagation, however this is the most common liver imaging technique used 
to detect the presence of steatosis. In B-mode images, steatosis appears as an increased 
parenchymal echogenicity caused by the increased reflectivity induced by fatty 
accumulation. This increased echogenicity is determined by the sonographer, most of the 
time by comparison with kidney echogenicity. Such as procedure it is highly operator- 
and machine-dependant. Many studies have reported averaged specificity and sensitivity 
of the technique as around 60-70%. Other studies have reported better specificity and 
sensitivity up to 95%, and therefore its performance in clinical practice is still 
controversial. Another limitation of US is that it cannot quantify steatosis and can only 
detect steatosis from around 30% of fatty infiltration, where there is a clinical relevance to 
detect lower extent of liver fat. 
Furthermore, some studies have shown that liver fibrosis can induce an increased liver 
echogenicity without posterior beam attenuation. It is therefore impossible to distinguish 
between increased echogenicity caused by an extensive fibrosis from increased echogenicity 
caused by fatty infiltration. A quantitative attenuation parameter can overcome this 
limitation. 
Recently a new parameter has been developed to detect and quantify degree of liver 
steatosis. This parameter is based on the US properties of the radiofrequency 
backpropagated signals acquired by the VCTE. It is called controlled attenuation 
parameter (CAP), because it was devised to specifically target the liver (Sasso et al, 2010). 
This coefficient is an estimate of the total US (go-and-return path) at 3.5 MHz and is 
expressed in decibel per meters (dB.m-1). CAP is evaluated using the same radio-
frequency data and in the same region of interest than the ones used for LSM and it is 
only appraised if the acquisition is valid. CAP is VCTE guided and obtains an ultrasonic 
attenuation value of the liver only. Therefore, CAP can be assessed by an operator who 
does not have any ultrasound imaging skills. Furthermore, CAP has been designed to be 
immediate, reproducible and operator and machine-independent. Performance of CAP 
was evaluated by Sasso et al. on 115 patients, taking the histological grade of steatosis as 
reference. Among those patients, 42 were CHC, 17 CBV, 39 with alcoholic liver disease 
and 17 with NAFLD. Mean BMI was 25 ± 4 kg/m2. CAP was significantly correlated to 
steatosis (P=10-16). AUROC was equal to 0.91 and 0.95 for the detection of more than 10% 
and 33% of steatosis, respectively. These data show that CAP can efficiently separate 
several steatosis grades. CAP appears to be a promising diagnostic tool for non-invasive 
assessment and quantification of steatosis, enhancing the spectrum of the non-invasive 
method for the exploration and follow-up of patients with fatty liver. However validation 






6. Conclusion  
LB will still be part of clinical practice in the coming years, but progress in medicine will 
challenge previously entrenched assumptions and will change our current approach to liver 
diseases in the next future. Non-invasive assessment of liver fibrosis is currently a reality in 
patients with CHC. In other highly prevalent diseases, such as NAFLD there is still room for 
improvement, although in the next few years LB will likely be supplanted in most cases. 
Many imaging techniques can be used to identify liver steatosis, such as computed 
tomography scans, magnetic resonance imaging or proton nuclear magnetic resonance. 
However all of these imaging tools present some important limitations: they are not easily 
available and their costs are relatively expensive (Sasso et al, 2010).  
VCTE is a simple, non-invasive and inexpensive method used to measure LS. The accuracy 
and reproducibility of VCTE score is excellent for the diagnosis of cirrhosis; it is probably 
the most accurate non-invasive method for the early detection of cirrhosis. It is a user-
friendly technique that can be performed without any preparation in the less than five 
minutes in clinic or at the bedside, with immediate results and high patient acceptance, it is 
very likely that in future it will become the most widely used technique for staging liver 
disease. A panel discussion is in progress to define the role of VCTE in the staging of liver 
disease. In particular, there are a few methodological approaches that need to be 
implemented in future studies designed to further validate LSM. A new statistical approach 
is needed in order to obtain reliable and clinically useful information from LSM (Vizzuti et 
al, 2009). In fact, most of the published studies reported the cut-off values selected by binary 
measures, like sensitivity and specificity. However, it seems insufficiently informative to 
discriminate the optimal cut-off value in a wide range of values, specially in a context of 
liver steatosis. A new parameter measuring the US attenuation could be interesting and 
might be related to steatosis. This indicator, called CAP, has been developed to process the 
raw ultrasonic signals stored in the VCTE examination file. Performance of CAP has to be 
validated into specific etiologic groups. In addiction influence of the steatosis topography 
and other histologic constituents, specific to each etiology has to be considered. Large 
cohorts are required to determine appropriate threshold to detect and quantify steatosis. 
Further technological improvements are requested for better application of this technique in 
specific populations, such as patients with increased BMI, along with efforts to improve and 
standardize the procedure and adequate operator training. 
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